Based on news reporting.
Tessera Therapeutics, a gene editing startup, has announced the layoff of 90 employees as it embarks on its first clinical study. This decision comes as part of the company's strategic adjustments during a critical phase of development. The layoffs reflect the company's efforts to streamline operations and focus resources on advancing its clinical initiatives. While the specific departments affected were not detailed, this move indicates a significant shift in the company's workforce strategy. The layoffs highlight the challenges faced by startups in the competitive biotech landscape.
Tessera Therapeutics cut 90 jobs as of January 8, 2026.
LayoffTalk has tracked 7 layoff events at Tessera Therapeutics since October 2023, affecting a combined 211 employees.
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Share your story anonymously — it helps others reading this feel less alone.
Share your story →Recent tracked events at this company.